JP2020519648A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020519648A5 JP2020519648A5 JP2019562632A JP2019562632A JP2020519648A5 JP 2020519648 A5 JP2020519648 A5 JP 2020519648A5 JP 2019562632 A JP2019562632 A JP 2019562632A JP 2019562632 A JP2019562632 A JP 2019562632A JP 2020519648 A5 JP2020519648 A5 JP 2020519648A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- fusosome
- composition according
- cells
- fusogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 117
- 210000004027 cell Anatomy 0.000 claims description 101
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims description 35
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 claims description 20
- 239000000232 Lipid Bilayer Substances 0.000 claims description 18
- 101710169105 Minor spike protein Proteins 0.000 claims description 14
- 101710081079 Minor spike protein H Proteins 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- 238000003556 assay Methods 0.000 claims description 11
- 230000003612 virological effect Effects 0.000 claims description 11
- 108091006027 G proteins Proteins 0.000 claims description 10
- 102000030782 GTP binding Human genes 0.000 claims description 10
- 108091000058 GTP-Binding Proteins 0.000 claims description 10
- 230000008685 targeting Effects 0.000 claims description 10
- 230000012202 endocytosis Effects 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 8
- 230000037361 pathway Effects 0.000 claims description 8
- 108090000565 Capsid Proteins Proteins 0.000 claims description 7
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000002458 cell surface marker Substances 0.000 claims description 6
- 210000000172 cytosol Anatomy 0.000 claims description 6
- 210000001808 exosome Anatomy 0.000 claims description 6
- 210000003494 hepatocyte Anatomy 0.000 claims description 6
- 238000004949 mass spectrometry Methods 0.000 claims description 5
- 210000002569 neuron Anatomy 0.000 claims description 5
- 102100025222 CD63 antigen Human genes 0.000 claims description 4
- 241000893570 Hendra henipavirus Species 0.000 claims description 4
- 241000035314 Henipavirus Species 0.000 claims description 4
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 claims description 4
- 241000712079 Measles morbillivirus Species 0.000 claims description 4
- 241000711408 Murine respirovirus Species 0.000 claims description 4
- 102000002278 Ribosomal Proteins Human genes 0.000 claims description 4
- 108010000605 Ribosomal Proteins Proteins 0.000 claims description 4
- 241000332040 Tupaia paramyxovirus Species 0.000 claims description 4
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 4
- 210000001163 endosome Anatomy 0.000 claims description 4
- 239000003344 environmental pollutant Substances 0.000 claims description 4
- 210000003714 granulocyte Anatomy 0.000 claims description 4
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 210000003712 lysosome Anatomy 0.000 claims description 4
- 230000001868 lysosomic effect Effects 0.000 claims description 4
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 4
- 210000003098 myoblast Anatomy 0.000 claims description 4
- 210000000440 neutrophil Anatomy 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 244000052769 pathogen Species 0.000 claims description 4
- 231100000719 pollutant Toxicity 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 230000007309 lysosomal acidification Effects 0.000 claims description 3
- 210000001116 retinal neuron Anatomy 0.000 claims description 3
- 210000000130 stem cell Anatomy 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 102000007469 Actins Human genes 0.000 claims description 2
- 108010085238 Actins Proteins 0.000 claims description 2
- 241000711950 Filoviridae Species 0.000 claims description 2
- 241000710781 Flaviviridae Species 0.000 claims description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims description 2
- 241000700739 Hepadnaviridae Species 0.000 claims description 2
- 201000005505 Measles Diseases 0.000 claims description 2
- 108010052285 Membrane Proteins Proteins 0.000 claims description 2
- 102000018697 Membrane Proteins Human genes 0.000 claims description 2
- 108010026552 Proteome Proteins 0.000 claims description 2
- 241000711931 Rhabdoviridae Species 0.000 claims description 2
- 241000710924 Togaviridae Species 0.000 claims description 2
- 101710120037 Toxin CcdB Proteins 0.000 claims description 2
- 210000002798 bone marrow cell Anatomy 0.000 claims description 2
- 210000004958 brain cell Anatomy 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 230000001086 cytosolic effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims description 2
- 230000002163 immunogen Effects 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 210000005265 lung cell Anatomy 0.000 claims description 2
- 230000002132 lysosomal effect Effects 0.000 claims description 2
- 230000034701 macropinocytosis Effects 0.000 claims description 2
- 230000002107 myocardial effect Effects 0.000 claims description 2
- 108010055837 phosphocarrier protein HPr Proteins 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 210000005267 prostate cell Anatomy 0.000 claims description 2
- 230000019491 signal transduction Effects 0.000 claims description 2
- 210000004927 skin cell Anatomy 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- SSCSSDNTQJGTJT-UHFFFAOYSA-N (3,6-dihydroxy-1-methyl-2,3-dihydroindol-5-yl)iminourea Chemical compound CN1CC(O)C2=CC(N=NC(N)=O)=C(O)C=C12 SSCSSDNTQJGTJT-UHFFFAOYSA-N 0.000 claims 2
- 101000930679 Nipah virus Fusion glycoprotein F0 Proteins 0.000 claims 2
- 241000711504 Paramyxoviridae Species 0.000 claims 2
- 210000001167 myeloblast Anatomy 0.000 claims 2
- 241000712892 Arenaviridae Species 0.000 claims 1
- 102000043859 Dynamin Human genes 0.000 claims 1
- 108700021058 Dynamin Proteins 0.000 claims 1
- 241000712045 Morbillivirus Species 0.000 claims 1
- 241000150350 Peribunyaviridae Species 0.000 claims 1
- 241000288754 Scandentia Species 0.000 claims 1
- 241000288667 Tupaia glis Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 claims 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 238000011194 good manufacturing practice Methods 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 241001113283 Respirovirus Species 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- QUTFFEUUGHUPQC-ILWYWAAHSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC1=CC=C([N+]([O-])=O)C2=NON=C12 QUTFFEUUGHUPQC-ILWYWAAHSA-N 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 241000590568 Dynamine Species 0.000 description 1
- 101710160621 Fusion glycoprotein F0 Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- OYTKINVCDFNREN-UHFFFAOYSA-N amifampridine Chemical compound NC1=CC=NC=C1N OYTKINVCDFNREN-UHFFFAOYSA-N 0.000 description 1
- XDHNQDDQEHDUTM-JQWOJBOSSA-N bafilomycin A1 Chemical compound CO[C@H]1\C=C\C=C(C)\C[C@H](C)[C@H](O)[C@H](C)\C=C(/C)\C=C(OC)\C(=O)O[C@@H]1[C@@H](C)[C@@H](O)[C@H](C)[C@]1(O)O[C@H](C(C)C)[C@@H](C)[C@H](O)C1 XDHNQDDQEHDUTM-JQWOJBOSSA-N 0.000 description 1
- XDHNQDDQEHDUTM-ZGOPVUMHSA-N bafilomycin A1 Natural products CO[C@H]1C=CC=C(C)C[C@H](C)[C@H](O)[C@H](C)C=C(C)C=C(OC)C(=O)O[C@@H]1[C@@H](C)[C@@H](O)[C@H](C)[C@]1(O)O[C@H](C(C)C)[C@@H](C)[C@H](O)C1 XDHNQDDQEHDUTM-ZGOPVUMHSA-N 0.000 description 1
- XDHNQDDQEHDUTM-UHFFFAOYSA-N bafliomycin A1 Natural products COC1C=CC=C(C)CC(C)C(O)C(C)C=C(C)C=C(OC)C(=O)OC1C(C)C(O)C(C)C1(O)OC(C(C)C)C(C)C(O)C1 XDHNQDDQEHDUTM-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-UKLRSMCWSA-N dextrose-2-13c Chemical compound OC[C@H]1OC(O)[13C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-UKLRSMCWSA-N 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023133407A JP7783858B2 (ja) | 2017-05-08 | 2023-08-18 | 膜融合を促進するための組成物およびその使用 |
| JP2025209141A JP2026031606A (ja) | 2017-05-08 | 2025-11-28 | 膜融合を促進するための組成物およびその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762502998P | 2017-05-08 | 2017-05-08 | |
| US62/502,998 | 2017-05-08 | ||
| US201762575147P | 2017-10-20 | 2017-10-20 | |
| US62/575,147 | 2017-10-20 | ||
| US201762595862P | 2017-12-07 | 2017-12-07 | |
| US62/595,862 | 2017-12-07 | ||
| PCT/US2018/031515 WO2018208728A1 (en) | 2017-05-08 | 2018-05-08 | Compositions for facilitating membrane fusion and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023133407A Division JP7783858B2 (ja) | 2017-05-08 | 2023-08-18 | 膜融合を促進するための組成物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020519648A JP2020519648A (ja) | 2020-07-02 |
| JP2020519648A5 true JP2020519648A5 (https=) | 2021-07-26 |
| JP7395355B2 JP7395355B2 (ja) | 2023-12-11 |
Family
ID=62555182
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019562632A Active JP7395355B2 (ja) | 2017-05-08 | 2018-05-08 | 膜融合を促進するための組成物およびその使用 |
| JP2023133407A Active JP7783858B2 (ja) | 2017-05-08 | 2023-08-18 | 膜融合を促進するための組成物およびその使用 |
| JP2025209141A Pending JP2026031606A (ja) | 2017-05-08 | 2025-11-28 | 膜融合を促進するための組成物およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023133407A Active JP7783858B2 (ja) | 2017-05-08 | 2023-08-18 | 膜融合を促進するための組成物およびその使用 |
| JP2025209141A Pending JP2026031606A (ja) | 2017-05-08 | 2025-11-28 | 膜融合を促進するための組成物およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11576872B2 (https=) |
| EP (2) | EP4647083A3 (https=) |
| JP (3) | JP7395355B2 (https=) |
| KR (2) | KR102761577B1 (https=) |
| CN (1) | CN110869507A (https=) |
| AU (2) | AU2018266111B2 (https=) |
| BR (1) | BR112019023323A2 (https=) |
| CA (1) | CA3062426A1 (https=) |
| DK (1) | DK3622079T3 (https=) |
| ES (1) | ES3052812T3 (https=) |
| IL (1) | IL270496B2 (https=) |
| MX (1) | MX2019013312A (https=) |
| WO (1) | WO2018208728A1 (https=) |
Families Citing this family (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10272137B2 (en) | 2013-06-27 | 2019-04-30 | The Board Of Regents Of The University Of Texas System | Compositions and methods relating to myomaker-induced muscle cell fusion |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US9816080B2 (en) | 2014-10-31 | 2017-11-14 | President And Fellows Of Harvard College | Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs) |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US12590321B2 (en) | 2016-03-19 | 2026-03-31 | Exuma Biotech Corp. | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| EP3235908A1 (en) | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
| US11730823B2 (en) | 2016-10-03 | 2023-08-22 | President And Fellows Of Harvard College | Delivery of therapeutic RNAs via ARRDC1-mediated microvesicles |
| US12390514B2 (en) | 2017-03-09 | 2025-08-19 | President And Fellows Of Harvard College | Cancer vaccine |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| WO2018201160A1 (en) | 2017-04-28 | 2018-11-01 | Agrospheres, Inc. | Compositions and methods for enzyme immobilization |
| CA3062426A1 (en) * | 2017-05-08 | 2018-11-15 | Flagship Pioneering Innovations V, Inc. | Compositions for facilitating membrane fusion and uses thereof |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| WO2019032628A1 (en) | 2017-08-07 | 2019-02-14 | The Regents Of The University Of California | GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS |
| US10960071B2 (en) | 2017-08-07 | 2021-03-30 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| CA3073449A1 (en) | 2017-09-25 | 2019-03-28 | Agrospheres, Inc. | Compositions and methods for scalable production and delivery of biologicals |
| US20210187018A1 (en) * | 2017-12-07 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Cytobiologics and therapeutic uses thereof |
| AU2019222560B2 (en) * | 2018-02-17 | 2025-07-03 | Flagship Pioneering Innovations V, Inc. | Compositions and methods for membrane protein delivery |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| CN112955174A (zh) * | 2018-07-09 | 2021-06-11 | 旗舰先锋创新V股份有限公司 | 融合剂脂质体组合物和其用途 |
| EP3880832A1 (en) * | 2018-11-14 | 2021-09-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for hematopoietic stem cell delivery |
| CN113631718A (zh) | 2018-11-14 | 2021-11-09 | 旗舰先锋创新V股份有限公司 | 用于特定隔室货物递送的组合物和方法 |
| US11166996B2 (en) | 2018-12-12 | 2021-11-09 | Flagship Pioneering Innovations V, Inc. | Anellovirus compositions and methods of use |
| CA3125567A1 (en) | 2019-01-18 | 2020-07-23 | Flagship Pioneering, Inc. | Trem compositions and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| US20220143062A1 (en) | 2019-03-04 | 2022-05-12 | Flagship Pioneering Innovations Vi, Llc | Circular polyribonucleotides and pharmaceutical compositions thereof |
| WO2020191233A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| WO2020198403A2 (en) | 2019-03-25 | 2020-10-01 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising modified circular polyribonucleotides and uses thereof |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US20220184225A1 (en) * | 2019-04-23 | 2022-06-16 | Case Western Reserve University | Fusogenic particles and related methods for delivering therapeutic agents to cells |
| EP3965829A4 (en) * | 2019-05-06 | 2023-05-24 | Malcolm, Thomas | ADAPTED HYPOIMMUNE NANOVESICULAR DELIVERY SYSTEM FOR CANCER TUMORS |
| WO2020243560A1 (en) | 2019-05-31 | 2020-12-03 | Flagship Pioneering, Inc. | Uses of trem compositions to modulate trna pools |
| WO2020252455A1 (en) | 2019-06-13 | 2020-12-17 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| JP2022537154A (ja) | 2019-06-14 | 2022-08-24 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | 細胞治療のための環状ｒｎａ |
| WO2020257730A1 (en) | 2019-06-19 | 2020-12-24 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides for protein modulation and uses thereof |
| CA3152525A1 (en) | 2019-09-03 | 2021-03-11 | Sana Biotechnology, Inc. | Cd24-associated particles and related methods and uses thereof |
| WO2021062196A1 (en) * | 2019-09-26 | 2021-04-01 | President And Fellows Of Harvard College | Minimal arrestin domain containing protein 1 (arrdc1) constructs |
| CA3160097A1 (en) | 2019-11-04 | 2021-05-14 | Flagship Pioneering, Inc. | Trem compositions for con-rare codons and related uses |
| WO2021092073A1 (en) | 2019-11-04 | 2021-05-14 | Flagship Pioneering, Inc. | Methods of modifying a nucleic acid sequence |
| CN111019882A (zh) * | 2019-12-10 | 2020-04-17 | 沈阳朗森特医疗器械有限公司 | 一种皮肤表皮干细胞外泌体的分离和纯化方法 |
| CN115361954A (zh) | 2020-01-29 | 2022-11-18 | 旗舰创业创新第六有限责任公司 | 用于翻译的组合物及其使用方法 |
| EP4096715A1 (en) | 2020-01-29 | 2022-12-07 | Flagship Pioneering Innovations VI, LLC | Compositions comprising linear polyribonucleotides for protein modulation and uses thereof |
| EP4096681A1 (en) | 2020-01-29 | 2022-12-07 | Flagship Pioneering Innovations VI, LLC | Delivery of compositions comprising circular polyribonucleotides |
| CA3178308A1 (en) * | 2020-03-31 | 2021-10-07 | Sana Biotechnology, Inc. | Targeted lipid particles and compositions and uses thereof |
| EP4153223A1 (en) | 2020-05-20 | 2023-03-29 | Flagship Pioneering Innovations VI, LLC | Immunogenic compositions and uses thereof |
| US20230203192A1 (en) | 2020-05-20 | 2023-06-29 | Flagship Pioneering, Inc. | Compositions and methods for producing human polyclonal antibodies |
| IL298362A (en) | 2020-05-20 | 2023-01-01 | Flagship Pioneering Innovations Vi Llc | Coronavirus antigen compositions and their uses |
| KR20230029685A (ko) | 2020-05-29 | 2023-03-03 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | Trem 조성물 및 이에 관련된 방법 |
| WO2021243301A2 (en) | 2020-05-29 | 2021-12-02 | Flagship Pioneering Innovations Vi, Llc. | Trem compositions and methods relating thereto |
| CN116234583A (zh) * | 2020-06-12 | 2023-06-06 | 哈佛大学的校长及成员们 | Arrdc1介导的基于微泡的向神经系统的递送 |
| US20230233514A1 (en) | 2020-06-23 | 2023-07-27 | Flagship Pioneering, Inc. | Antiviral compounds and methods of using the same |
| AU2021305060A1 (en) * | 2020-07-06 | 2023-02-09 | Flagship Pioneering Innovations V, Inc. | Methods and compositions for producing viral fusosomes |
| CA3189601A1 (en) | 2020-07-24 | 2022-01-27 | The General Hospital Corporation | Enhanced virus-like particles and methods of use thereof for delivery to cells |
| AU2021336976A1 (en) | 2020-09-03 | 2023-03-23 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
| AU2021369747A1 (en) * | 2020-10-31 | 2023-06-08 | Children's Hospital Medical Center | Pseudotyped particles, modified cells, related compositions, and related methods |
| IL303886A (en) | 2020-12-23 | 2023-08-01 | Flagship Pioneering Inc | Compositions of modified trems and uses thereof |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| KR20240028975A (ko) | 2021-04-08 | 2024-03-05 | 사나 바이오테크놀로지, 인크. | Cd8-특이적 항체 구조체들 및 이의 조성물 |
| CN113262212A (zh) * | 2021-04-26 | 2021-08-17 | 北京大学口腔医学院 | 一种靶向炎症区域的细胞膜微囊泡及其应用 |
| JP2024521811A (ja) | 2021-05-28 | 2024-06-04 | サナ バイオテクノロジー，インコーポレイテッド | 短縮型ヒヒ内在性レトロウイルス（ＢａＥＶ）エンベロープ糖タンパク質を含む脂質粒子、ならびに関連する方法及び使用 |
| EP4377457A1 (en) | 2021-07-26 | 2024-06-05 | Flagship Pioneering Innovations VI, LLC | Trem compositions and uses thereof |
| MX2024003262A (es) | 2021-09-17 | 2024-06-19 | Flagship Pioneering Innovations Vi Llc | Composiciones y metodos para producir poliribonucleotidos circulares. |
| CA3235625A1 (en) | 2021-10-18 | 2023-04-27 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
| IL312965A (en) | 2021-11-24 | 2024-07-01 | Flagship Pioneering Innovations Vi Llc | Immunogenic compositions and their uses |
| EP4436984A1 (en) | 2021-11-24 | 2024-10-02 | Flagship Pioneering Innovations VI, LLC | Coronavirus immunogen compositions and their uses |
| CN118401544A (zh) | 2021-11-24 | 2024-07-26 | 旗舰创业创新六公司 | 水痘-带状疱疹病毒免疫原组合物及其用途 |
| US20250059239A1 (en) | 2021-12-17 | 2025-02-20 | Sana Biotechnology, Inc. | Modified paramyxoviridae fusion glycoproteins |
| WO2023115041A1 (en) | 2021-12-17 | 2023-06-22 | Sana Biotechnology, Inc. | Modified paramyxoviridae attachment glycoproteins |
| EP4453201A1 (en) | 2021-12-22 | 2024-10-30 | Flagship Pioneering Innovations VI, LLC | Compositions and methods for purifying polyribonucleotides |
| KR20240118881A (ko) | 2021-12-23 | 2024-08-05 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 항푸소제닉 폴리펩티드를 인코딩하는 원형 폴리리보뉴클레오티드 |
| US20250205357A1 (en) * | 2022-03-11 | 2025-06-26 | President And Fellows Of Harvard College | Targeted delivery of armms |
| CA3257006A1 (en) | 2022-05-09 | 2023-11-16 | Flagship Pioneering Innovations Vi, Llc | TREM COMPOSITIONS AND METHODS OF USE FOR TREATING PROLIFERATIVE DISORDERS |
| TW202409283A (zh) | 2022-05-13 | 2024-03-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 雙股ｄｎａ組合物及相關方法 |
| US20250179492A1 (en) | 2022-06-22 | 2025-06-05 | Flagship Pioneering Innovations Vi, Llc | Compositions of modified trems and uses thereof |
| US20260055146A1 (en) | 2022-08-24 | 2026-02-26 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
| WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| EP4612296A1 (en) | 2022-10-31 | 2025-09-10 | Flagship Pioneering Innovations VI, LLC | Compositions and methods for purifying polyribonucleotides |
| TW202434728A (zh) | 2022-11-08 | 2024-09-01 | 美商旗艦先鋒創新有限責任公司 | 用於產生環狀多核糖核苷酸的組成物和方法 |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| TW202430215A (zh) | 2022-12-14 | 2024-08-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 用於將治療劑遞送至骨之組成物和方法 |
| US20240252520A1 (en) | 2023-01-09 | 2024-08-01 | Beth Israel Deaconess Medical Center, Inc. | Therapeutic agents and their use for treating chronic wounds |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| WO2024151673A2 (en) | 2023-01-09 | 2024-07-18 | President And Fellows Of Harvard College | Recombinant nucleic acid molecules and their use in wound healing |
| EP4665405A1 (en) | 2023-02-17 | 2025-12-24 | Flagship Pioneering Innovations VII, LLC | Dna compositions comprising modified uracil |
| IL322378A (en) | 2023-02-17 | 2025-09-01 | Flagship Pioneering Innovations Vii Llc | DNA compositions containing modified cytosine |
| CN121358494A (zh) | 2023-03-15 | 2026-01-16 | 旗舰创业创新第六有限责任公司 | 免疫原性组合物及其用途 |
| EP4680750A1 (en) | 2023-03-15 | 2026-01-21 | Flagship Pioneering Innovations VI, LLC | Compositions comprising polyribonucleotides and uses thereof |
| TW202506990A (zh) * | 2023-03-30 | 2025-02-16 | 艾萬霖生技股份有限公司 | 放射性標記的外泌體及其製備方法和套組 |
| EP4695391A1 (en) | 2023-04-12 | 2026-02-18 | Flagship Pioneering Innovations VI, LLC | Trems for use in correction of missense mutations |
| WO2024220560A1 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Engineered protein g fusogens and related lipid particles and methods thereof |
| EP4698666A1 (en) | 2023-04-18 | 2026-02-25 | Sana Biotechnology, Inc. | Universal protein g fusogens and adapter systems thereof and related lipid particles and uses |
| WO2024238808A2 (en) * | 2023-05-16 | 2024-11-21 | Vesigen, Inc. | Arrdc1-mediated microvesicle-based inflammation modulation |
| EP4716750A1 (en) | 2023-05-23 | 2026-04-01 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| WO2025006684A1 (en) | 2023-06-28 | 2025-01-02 | Flagship Pioneering Innovations Vi, Llc | Circular polyribonucleotides encoding antifusogenic polypeptides |
| WO2025042786A1 (en) | 2023-08-18 | 2025-02-27 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides and uses thereof |
| WO2025096807A2 (en) | 2023-10-31 | 2025-05-08 | Flagship Pioneering Innovations Vii, Llc | Novel therapeutic dna forms |
| CN117487737B (zh) * | 2023-12-26 | 2024-04-12 | 汕头大学 | 一种含Fe3O4纳米颗粒的去核细胞及其制备与在抗衰老中的应用 |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| US20260000702A1 (en) | 2024-06-26 | 2026-01-01 | Flagship Pioneering Innovations Vii, Llc | Therapeutic circular dna forms |
| WO2026055543A1 (en) | 2024-09-06 | 2026-03-12 | Flagship Pioneering Innovations Vii, Llc | Modified dna compositions and related methods |
| WO2026055547A1 (en) | 2024-09-06 | 2026-03-12 | Flagship Pioneering Innovations Vii, Llc | Dna compositions and related methods |
| WO2026064313A1 (en) | 2024-09-17 | 2026-03-26 | Flagship Pioneering Innovations Vii, Llc | Rna compositions and related methods |
| CN119246717B (zh) * | 2024-09-30 | 2026-02-17 | 集美大学 | 一种用于线粒体纯度评价的联合型代谢标志物及检测试剂盒 |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69333115D1 (de) | 1992-09-22 | 2003-08-28 | Biofocus Discovery Ltd | Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren |
| CA2186636A1 (en) | 1994-03-30 | 1995-10-12 | Corinna Herrnstadt | Diagnosis, therapy and cellular and animal models for diseases associated with mitochondrial defects |
| AU2589095A (en) | 1994-05-16 | 1995-12-05 | Washington University | Cell membrane fusion composition and method |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6165442A (en) | 1996-02-19 | 2000-12-26 | Nycomed Imaging As | Thermally stabilized ultrasound contrast agent |
| HUP0000522A3 (en) | 1996-10-15 | 2000-10-30 | Transave Inc Monmouth Junction | N-acyl phoshpatidylethanolamine-mediated liposomal drug delivery |
| WO1999013905A1 (en) | 1997-09-18 | 1999-03-25 | The Trustees Of The University Of Pennsylvania | Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery |
| US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| DE69938931D1 (de) | 1998-09-23 | 2008-07-31 | Inst Virologie Teilrechtsfaehi | Retrovirale partikel, geschützt gegen komplementvermittelte lyse |
| WO2001074861A2 (en) | 2000-03-31 | 2001-10-11 | Mayo Foundation For Medical Education And Research | Compositions and methods for tissue specific gene regulation therapy |
| CA2325088A1 (en) | 2000-12-01 | 2002-06-01 | Fusogenix Inc. | Novel membrane fusion proteins derived from poikilothermic reovirus |
| ATE508363T1 (de) | 2000-12-06 | 2011-05-15 | Ecole Polytech | Verfahren zur herstellung eines bioanalytischen reagenzes, nachweisverfahren beruhend auf der verwendung des bioanalytischen reagenz, sowie dessen verwendung |
| ES2387886T3 (es) | 2001-11-13 | 2012-10-03 | Celator Pharmaceuticals, Inc. | Composiciones que transportan lípidos con una mejor estabilidad sanguínea |
| US20040028687A1 (en) | 2002-01-15 | 2004-02-12 | Waelti Ernst Rudolf | Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues |
| AU2003258060B2 (en) | 2002-03-27 | 2007-07-12 | Baylor College Of Medicine | Potent oncolytic herpes simplex virus for cancer therapy |
| EP2339010B1 (en) | 2002-05-01 | 2017-04-12 | Miltenyi Biotec Technology, Inc. | Lentiviral vector particles resistant to complement inactivation |
| EP1549672B1 (en) | 2002-05-03 | 2010-09-01 | Mayo Foundation For Medical Education And Research | Ablated slam-dependent cell entry |
| US20060193905A1 (en) | 2002-05-14 | 2006-08-31 | University Of Louisville Research Foundation, Inc. | Direct cellular energy delivery system |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| WO2004045582A1 (en) | 2002-11-21 | 2004-06-03 | Pevion Biotech Ltd. | High-efficiency fusogenic vesicles, methods of producing them, and pharmaceutical compositions containing them |
| EP1651667B1 (en) | 2003-04-04 | 2012-03-28 | Centre National De La Recherche Scientifique | Protein with fusogenic activity, nucleic acid sequences encoding said protein and pharmaceutical compositions comprising the same |
| CA2532228C (en) | 2003-07-16 | 2017-02-14 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
| EP1664316B1 (en) | 2003-09-15 | 2012-08-29 | Protiva Biotherapeutics Inc. | Polyethyleneglycol-modified lipid compounds and uses thereof |
| WO2005059111A2 (en) | 2003-12-17 | 2005-06-30 | The Trustees Of Columbia University In The City Of New York | DELIVERY OF DNA OR RNA VIA GAP JUNCTIONS FROM HOST CELLS TO TARGET CELLS AND A CELL-BASED DELIVERY SYSTEM FOR ANTISENSE OR SiRNA |
| JP4764426B2 (ja) | 2004-06-07 | 2011-09-07 | プロチバ バイオセラピューティクス インコーポレイティッド | カチオン性脂質および使用方法 |
| CA2569664C (en) | 2004-06-07 | 2013-07-16 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
| WO2006080951A2 (en) | 2004-07-01 | 2006-08-03 | Yale University | Targeted and high density drug loaded polymeric materials |
| GB0416120D0 (en) | 2004-07-19 | 2004-08-18 | Health Prot Agency | Stable compositions containing OMV's |
| US20060045910A1 (en) * | 2004-09-02 | 2006-03-02 | Ehringer William D | Preserved fusogenic vesicles |
| WO2006027202A1 (en) | 2004-09-06 | 2006-03-16 | Unite De Recherche En Biotherapie Et Oncologie (Rubio) | Generation of multiparent cell hybrids |
| GB0426641D0 (en) * | 2004-12-03 | 2005-01-05 | Bioactive Protein Delivery The | Protein delivery system |
| CA2609142C (en) | 2005-05-27 | 2016-02-09 | Fondazione Centro San Raffaele Del Monte Tabor | Therapeutic gene vectors comprising mirna target sequences |
| WO2007048046A2 (en) | 2005-10-20 | 2007-04-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of filovirus gene expression |
| CN101346393B (zh) | 2005-11-02 | 2015-07-22 | 普洛体维生物治疗公司 | 修饰的siRNA分子及其应用 |
| WO2007099387A1 (en) | 2006-03-03 | 2007-09-07 | Mymetics Corporation | Virosome-like vesicles comprising gp41-derived antigens |
| WO2007127848A1 (en) | 2006-04-26 | 2007-11-08 | University Of Louisville Research Foundation, Inc | Isolation of membrane vesicles from biological fluids and methods of using same |
| US9085778B2 (en) | 2006-05-03 | 2015-07-21 | VL27, Inc. | Exosome transfer of nucleic acids to cells |
| US7915399B2 (en) | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
| US20120121650A1 (en) | 2006-08-18 | 2012-05-17 | Johnston Robert E | Chimeric Virus Vaccines |
| WO2008071959A1 (en) | 2006-12-12 | 2008-06-19 | Oxford Biomedica (Uk) Limited | Lentiviral vectors comprising micrornas |
| EP2020221B1 (de) | 2007-06-19 | 2012-02-29 | Neubourg Skin Care GmbH & Co. KG | DMS (Derma Membrane Structure) in Schaum-Cremes |
| GB0713672D0 (en) | 2007-07-13 | 2007-08-22 | Imp Innovations Ltd | Method for cell manipulation |
| EP2254586B1 (en) | 2008-02-22 | 2015-04-08 | Agency For Science, Technology And Research (A*star) | Mesenchymal stem cell particles |
| CA2721333C (en) | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
| CA2722238C (en) | 2008-04-22 | 2017-11-28 | Life Sciences Research Partners Vzw | Liver-specific nucleic acid regulatory elements and methods and use thereof |
| US9060926B2 (en) | 2008-10-31 | 2015-06-23 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US9050251B2 (en) | 2008-10-31 | 2015-06-09 | The Invention Science Fund I, Llc | Compositions and methods for delivery of frozen particle adhesives |
| WO2010053489A1 (en) | 2008-11-07 | 2010-05-14 | Children's Hospital Medical Center | Fusogenic properties of saposin c and related proteins and peptides for application to transmembrane drug delivery systems |
| EP2364362B1 (en) | 2008-11-12 | 2015-10-21 | Ospedale San Raffaele S.r.l. | Gene vector for inducing transgene-specific immune tolerance |
| WO2011000107A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
| CN102596177B (zh) | 2009-07-01 | 2014-05-28 | 阿昂梅迪克斯公司 | 来源于有核哺乳动物细胞的微囊泡及其应用 |
| EP2449106B1 (en) | 2009-07-01 | 2015-04-08 | Protiva Biotherapeutics Inc. | Compositions and methods for silencing apolipoprotein b |
| RS53257B2 (sr) | 2009-07-24 | 2018-06-29 | Immune Design Corp | Lentiviralni vektori pseudotipizirani sa omotačem od glikobelančevine iz sindbis-virusa |
| WO2011024172A2 (en) | 2009-08-27 | 2011-03-03 | Technion Research & Development Foundation Ltd. | Liposomal compositions and uses of same |
| EP2498823B1 (en) | 2009-11-13 | 2018-08-29 | INSERM - Institut National de la Santé et de la Recherche Médicale | Direct protein delivery with engineered microvesicles |
| CA2813300A1 (en) | 2010-09-29 | 2012-04-05 | Innovascreen Inc. | Recombinant polypeptides for membrane fusion and uses thereof |
| AU2012249474A1 (en) * | 2011-04-28 | 2013-11-07 | Stc.Unm | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same |
| GB201121069D0 (en) | 2011-12-07 | 2012-01-18 | Isis Innovation | Delivery system |
| GB201121070D0 (en) | 2011-12-07 | 2012-01-18 | Isis Innovation | composition for delivery of biotherapeutics |
| ES2661236T3 (es) | 2011-12-13 | 2018-03-28 | Henry Ford Health System | Procedimientos, sistemas y composiciones para administración de microARN derivado de células/a base de vesículas |
| WO2013119602A1 (en) | 2012-02-06 | 2013-08-15 | President And Fellows Of Harvard College | Arrdc1-mediated microvesicles (armms) and uses thereof |
| CA2870593A1 (en) * | 2012-04-16 | 2013-10-24 | Board Of Regents, The University Of Texas System | Detection of extracellular jcv micrornas |
| US20150133420A1 (en) * | 2012-05-04 | 2015-05-14 | The Regents Of The University Of California | Broad antiviral therapy with membrane modifying oxysterols |
| WO2014063757A1 (en) | 2012-10-26 | 2014-05-01 | Universiteit Leiden | Delivery methods |
| CN105051192B (zh) | 2012-11-13 | 2020-04-17 | 科迪艾克生物科学公司 | 治疗剂的递送 |
| CA2910802A1 (en) | 2013-04-12 | 2014-10-16 | Samir El Andaloussi | Therapeutic delivery vesicles |
| EP3008192B1 (en) | 2013-06-11 | 2019-07-17 | Takara Bio USA, Inc. | Protein enriched microvesicles and methods of making and using the same |
| GB201313249D0 (en) | 2013-07-25 | 2013-09-11 | Isis Innovation | Method |
| US10272137B2 (en) | 2013-06-27 | 2019-04-30 | The Board Of Regents Of The University Of Texas System | Compositions and methods relating to myomaker-induced muscle cell fusion |
| KR20150052667A (ko) | 2013-11-06 | 2015-05-14 | 삼성전자주식회사 | 시료 중 소포를 안정화시키는 방법 |
| KR102396026B1 (ko) | 2014-01-21 | 2022-05-09 | 안자리움 바이오사이언시스 아게 | 하이브리도좀, 이를 포함하는 조성물, 이의 제조 방법 및 이의 용도 |
| GB201412494D0 (en) | 2014-07-14 | 2014-08-27 | Ospedale San Raffaele And Fond Telethon | Vector production |
| WO2016057755A1 (en) | 2014-10-09 | 2016-04-14 | Anthrogenesis Corporation | Placenta-derived adherent cell exosomes and uses thereof |
| US9816080B2 (en) | 2014-10-31 | 2017-11-14 | President And Fellows Of Harvard College | Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs) |
| WO2016077639A2 (en) | 2014-11-12 | 2016-05-19 | VL27, Inc. | Nanovesicular therapies |
| WO2016138525A1 (en) | 2015-02-27 | 2016-09-01 | University Of Washington | Polypeptide assemblies and methods for the production thereof |
| US9687511B2 (en) | 2015-03-06 | 2017-06-27 | Vivex Biomedical, Inc. | Acellular biologic composition and method of manufacture |
| US20180135012A1 (en) | 2015-05-13 | 2018-05-17 | Rubius Therapeutics, Inc. | Membrane-receiver complex therapeutics |
| US11077147B2 (en) | 2015-07-20 | 2021-08-03 | Vivex Biologics Group, Inc. | Acellular biologic composition and method of manufacture |
| US10624849B2 (en) | 2015-09-28 | 2020-04-21 | Northwestern University | Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites |
| US20170112773A1 (en) | 2015-10-23 | 2017-04-27 | Board Of Regents, The University Of Texas System | Plasma membrane vesicles comprising functional transmembrane proteins |
| US11903974B2 (en) | 2015-11-30 | 2024-02-20 | Flagship Pioneering Innovations V, Inc. | Methods and compositions relating to chondrisomes from cultured cells |
| US10316295B2 (en) | 2015-12-17 | 2019-06-11 | The Penn State Research Foundation | Paramyxovirus virus-like particles as protein delivery vehicles |
| EP3397264A4 (en) | 2015-12-30 | 2019-06-05 | The Regents of The University of California | METHOD FOR IMPROVED PREPARATION AND INSULATION OF CELL-DERIVED VESICLES |
| EP3402489B1 (en) | 2016-01-15 | 2021-06-09 | Orbsen Therapeutics Limited | Sdc-2 exosome compositions and methods of isolation and use |
| WO2017151717A1 (en) | 2016-03-01 | 2017-09-08 | French Brent A | Compositions and methods for adeno-associated virus mediated gene expression in myofibroblast-like cells |
| CA3017586A1 (en) | 2016-03-15 | 2017-09-21 | Codiak Biosciences, Inc. | Therapeutic membrane vesicles |
| EP3235908A1 (en) | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
| WO2017211945A1 (en) | 2016-06-09 | 2017-12-14 | Alma Mater Studiorum Universita Di Bologna | Herpesvirus with modified glycoprotein h for propagation in a cell |
| CA3030003A1 (en) | 2016-07-08 | 2018-01-11 | F1 Oncology, Inc. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US20180028600A1 (en) | 2016-07-15 | 2018-02-01 | Korea Institute Of Science And Technology | Novel recombinant exosome and use thereof |
| WO2018022747A1 (en) | 2016-07-26 | 2018-02-01 | Senti Biosciences, Inc. | Genetic erasers |
| CA3062426A1 (en) | 2017-05-08 | 2018-11-15 | Flagship Pioneering Innovations V, Inc. | Compositions for facilitating membrane fusion and uses thereof |
| AU2019215063B2 (en) | 2018-02-01 | 2025-10-16 | Bioverativ Therapeutics, Inc. | Use of lentiviral vectors expressing Factor VIII |
| SG11202011015QA (en) | 2018-05-15 | 2020-12-30 | Flagship Pioneering Innovations V Inc | Fusosome compositions and uses thereof |
| WO2020210003A2 (en) * | 2019-03-21 | 2020-10-15 | Georgia State University Research Foundation, Inc. | Virus-like particles and uses thereof |
-
2018
- 2018-05-08 CA CA3062426A patent/CA3062426A1/en active Pending
- 2018-05-08 US US16/611,768 patent/US11576872B2/en active Active
- 2018-05-08 WO PCT/US2018/031515 patent/WO2018208728A1/en not_active Ceased
- 2018-05-08 CN CN201880045196.2A patent/CN110869507A/zh active Pending
- 2018-05-08 IL IL270496A patent/IL270496B2/en unknown
- 2018-05-08 KR KR1020197036187A patent/KR102761577B1/ko active Active
- 2018-05-08 JP JP2019562632A patent/JP7395355B2/ja active Active
- 2018-05-08 DK DK18729845.0T patent/DK3622079T3/da active
- 2018-05-08 MX MX2019013312A patent/MX2019013312A/es unknown
- 2018-05-08 ES ES18729845T patent/ES3052812T3/es active Active
- 2018-05-08 EP EP25191444.6A patent/EP4647083A3/en active Pending
- 2018-05-08 BR BR112019023323-7A patent/BR112019023323A2/pt unknown
- 2018-05-08 EP EP18729845.0A patent/EP3622079B1/en active Active
- 2018-05-08 KR KR1020257002716A patent/KR20250021608A/ko active Pending
- 2018-05-08 AU AU2018266111A patent/AU2018266111B2/en active Active
-
2023
- 2023-01-13 US US18/154,618 patent/US20240033227A1/en active Pending
- 2023-08-18 JP JP2023133407A patent/JP7783858B2/ja active Active
-
2025
- 2025-02-04 AU AU2025200749A patent/AU2025200749A1/en active Pending
- 2025-11-28 JP JP2025209141A patent/JP2026031606A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020519648A5 (https=) | ||
| US20240238210A1 (en) | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis | |
| US12006508B2 (en) | Methods and products for expressing proteins in cells | |
| US11708396B2 (en) | Signal-sensor polynucleotides for the alteration of cellular phenotypes | |
| JP7047002B2 (ja) | 化学修飾ｍＲＮＡ | |
| JP6208750B2 (ja) | メッセンジャーｒｎａの肺送達 | |
| JP2024507394A (ja) | エアロゾル形成用の製剤および核酸を送達するためのエアロゾル | |
| JP7306721B2 (ja) | ウイルス様粒子及びその使用 | |
| JP2020502124A (ja) | 核酸および／またはタンパク質ペイロード送達のための組成物および方法 | |
| JP7658579B2 (ja) | 操作された長鎖散在反復エレメント（ｌｉｎｅ）トランスポゾンおよびそれらの使用方法 | |
| Stevanovic et al. | CRISPR systems suitable for single AAV vector delivery | |
| Basalova et al. | State-of-the-art: the use of extracellular vesicles and preparations based on them for neuroprotection and stimulation of brain tissue regeneration after injury | |
| Inagaki | mRNA: A Novel Tool for Cell Reprogramming and Differentiation in Regenerative Medicine | |
| WO2025096986A1 (en) | Gene editing methods and materials for adult onset leukoencephalopathy | |
| WO2025137275A1 (en) | Novel cas nucleases and polynucleotides encoding the same | |
| Awan et al. | Application of Advanced CRISPR/Cas-9 | |
| WO2024229321A1 (en) | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis | |
| WO2025180419A1 (zh) | 一种脱氨酶变体、包含其的碱基编辑器及其应用 |